BioArctic

BioArctic is a biopharmaceutical company focused on research. In order to advance significant ground-breaking discoveries made by Professor Lars Lannfelt on Alzheimer's disease, the company was established in 2003 by Dr. Pär Gellerfors and Professor Lars Lannfelt. These discoveries—the Swedish mutation and the Arctic mutation—have garnered significant international attention and shed light on the crucial function that amyloid-beta plays in Alzheimer's disease. As a result, novel therapeutic approaches have been created.

When the company's first medication candidate antibody, BAN2401 for Alzheimer's disease, was developed, BioArctic created a patented technology platform that proved successful. A biotech business called SynAct Pharma seeks to reduce inflammation by utilizing melanocortin biology. Phase 2 rheumatoid arthritis drug development is underway for their lead asset, AP1189. A once-daily tablet form of the immunomodulatory small molecule AP1189 is available.

With the completion of the purchase of TXP Pharma AG in January 2023, SynAct greatly increased the scope of its melanocortin technology portfolio by adding complementary peptide agonists that could be tailored to a variety of autoimmune and inflammatory disorders. This is one of the largest biotech companies in SS

Founded: 2003

Number of employees: 28 employees

Headquarters: Stockholm, Stockholms Lan, Sweden

Website: https://synactpharma.com/en/